Clinical Trial

A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of the study to evaluate the safety and efficacy of SKB571 for injection as monotherapy in patients with locally advanced or metastatic Non-Small Cell Lung Cancer with MET abnormalities. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.
Protocol Amendment History 2 changes
notable Enrollment increased: 60 -> 70 participants 2026-07-31
critical Recruitment opened 2026-05-02
Trial Details
NCT Number NCT07308106
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Non-small Lung Cancer
Enrollment 70 participants
Start Date 2026-04-03
Primary Completion 2027-06-30 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30